# Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD

> **NCT06969573** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Alberta** · enrollment: 20 (actual)

## Conditions studied

- COPD (Chronic Obstructive Pulmonary Disease)

## Interventions

- **DRUG:** Placebo
- **COMBINATION_PRODUCT:** Treprostinil Inhalation Solution 36 mcg
- **COMBINATION_PRODUCT:** Treprostinil Inhalation Solution 78 mcg

## Key facts

- **NCT ID:** NCT06969573
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-05
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06969573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06969573, "Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06969573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*